Synaffix Licenses CliCr Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

• Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology 
• CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry.

Under the terms of the agreement, Synaffix will obtain exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology. This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager applications.